Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co‐targeting bromodomain and extra‐terminal proteins and
MCL1
induces synergistic cell death in melanoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-04-06
DOI
10.1002/ijc.33000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax in the treatment of chronic lymphocytic leukemia
- (2019) Anna Korycka-Wolowiec et al. Expert Opinion on Drug Metabolism & Toxicology
- Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
- (2019) Abdullah Al Emran et al. TRENDS IN IMMUNOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Selective targeting of antiapoptotic BCL-2 proteins in cancer
- (2018) Ahmet Can Timucin et al. MEDICINAL RESEARCH REVIEWS
- The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
- (2018) A. Esteve-Arenys et al. ONCOGENE
- Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
- (2018) Ryan S. Soderquist et al. Nature Communications
- A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia
- (2018) Haley E. Ramsey et al. Cancer Discovery
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy
- (2018) Ryuji Yamaguchi et al. PHARMACOLOGY & THERAPEUTICS
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
- (2017) Stuart J. Gallagher et al. INTERNATIONAL JOURNAL OF CANCER
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
- (2017) Delphine Merino et al. Science Translational Medicine
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Role of the pro-survival molecule Bfl-1 in melanoma
- (2015) C.K. Hind et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes
- (2015) Jessamy C. Tiffen et al. Oncotarget
- The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells
- (2014) Stuart J. Gallagher et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151
- (2014) Stuart J. Gallagher et al. Pigment Cell & Melanoma Research
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
- (2013) T M Becker et al. ONCOGENE
- NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1
- (2012) A Craxton et al. CELL DEATH AND DIFFERENTIATION
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
- (2011) K. M. Lucas et al. CLINICAL CANCER RESEARCH
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress
- (2011) L Dong et al. ONCOGENE
- Mcl-1; the molecular regulation of protein function
- (2010) Luke W. Thomas et al. FEBS LETTERS
- Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Upregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells
- (2010) H.-Y. Tseng et al. MOLECULAR CANCER THERAPEUTICS
- Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis
- (2010) M Hörnle et al. ONCOGENE
- Treatment combinations targeting apoptosis to improve immunotherapy of melanoma
- (2009) Peter Hersey et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The NF- B Family of Transcription Factors and Its Regulation
- (2009) A. Oeckinghaus et al. Cold Spring Harbor Perspectives in Biology
- Up-regulation of Mcl-1 Is Critical for Survival of Human Melanoma Cells upon Endoplasmic Reticulum Stress
- (2008) C. C. Jiang et al. CANCER RESEARCH
- Tumour cell survival signalling by the ERK1/2 pathway
- (2008) K Balmanno et al. CELL DEATH AND DIFFERENTIATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started